Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 113

Results For "improve"

2641 News Found

Pfizer and BioNTech receive positive CHMP opinion for Omicron KP.2-adapted COVID-19
News | September 23, 2024

Pfizer and BioNTech receive positive CHMP opinion for Omicron KP.2-adapted COVID-19

Doses will be ready to ship to applicable European Union (EU) member states as soon as possible upon European Commission (EC) authorization


Pharmaceutical sector set for 8-10% revenue growth this fiscal: CRISIL
News | September 20, 2024

Pharmaceutical sector set for 8-10% revenue growth this fiscal: CRISIL

Stable profits, low leverage to keep credit profiles comfortable


Wockhardt's Zaynich cures complex case of meningitis caused by pan-drug resistant super-bug  under compassionate use
News | September 20, 2024

Wockhardt's Zaynich cures complex case of meningitis caused by pan-drug resistant super-bug under compassionate use

A multi-disciplinary team of senior physicians opted to use Zidebactam/Cefepime under compassionate use


Merck receives positive EU CHMP opinions for pembrolizumab regimens for gynecologic cancers
Clinical Trials | September 20, 2024

Merck receives positive EU CHMP opinions for pembrolizumab regimens for gynecologic cancers

Positive opinion granted for KEYTRUDA plus chemotherapy for the first-line treatment of adult patients with primary advanced or recurrent endometrial carcinoma


Keytruda plus chemotherapy before surgery reduced risk of death by more than 1/3versus neoadjuvant chemotherapy in high-risk early stage TNBC
Clinical Trials | September 16, 2024

Keytruda plus chemotherapy before surgery reduced risk of death by more than 1/3versus neoadjuvant chemotherapy in high-risk early stage TNBC

KEYTRUDA is the first and only immunotherapy-based regimen to show a statistically significant and clinically meaningful improvement in overall survival


10 year data for Merck’s Keytruda demonstrates sustained overall survival benefit versus Ipilimumab in advanced melanoma
Clinical Trials | September 16, 2024

10 year data for Merck’s Keytruda demonstrates sustained overall survival benefit versus Ipilimumab in advanced melanoma

At 10 years, more than one-third (34.0%) of patients with advanced melanoma were alive after treatment with KEYTRUDA, compared to 23.6% of patients treated with ipilimumab


FDA approves Roche’s Tecentriq Hybreza, the first and only subcutaneous anti-PD-(L) cancer immunotherapy
Drug Approval | September 16, 2024

FDA approves Roche’s Tecentriq Hybreza, the first and only subcutaneous anti-PD-(L) cancer immunotherapy

Tecentriq Hybreza provides patients and physicians with greater flexibility of treatment options while showing safety and efficacy consistent with intravenous


Ayush Ministry resolves 1346 Public Grievances under the Special Campaign 3.0
News | September 12, 2024

Ayush Ministry resolves 1346 Public Grievances under the Special Campaign 3.0

Secretary Vaidya Rajesh Kotecha has urged senior officials to strive for the successful attainment of targets during the campaign


Merck launches single-use reactor to accelerate ADC manufacturing
News | September 12, 2024

Merck launches single-use reactor to accelerate ADC manufacturing

Increases efficiency by 70% compared to stainless steel or glass manufacturing methods